Riskpilot← Back to searchSign inGet full accessBiogenity ApS
APSActiveCVR 39606925Niels Jernes Vej 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20185 employeeshttps://biogenity.com
Revenue 2025
DKK 1,4M
-27% vs 2024
EBITDA margin
-40.3%
-30% vs 2024
Equity ratio
-10.8%
Financial strength
Net profit 2025
DKK -454K
-32% vs 2024
| Revenue | DKK 1,4M | -27% |
| EBITDA | DKK -559K | -30% |
| Net profit | DKK -454K | -32% |
| Total assets | DKK 1,8M | +67% |
| Equity | DKK -190K | -172% |
| Employees | 5 | — |
Legal name
Biogenity ApS
CVR number
39606925
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30. maj 2018
Share capital
DKK 80.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen i forening.
Company purpose
Selskabets formål er at fungere som dataanalysebureau for den farmaceutiske industri.
Address
Niels Jernes Vej 10
Phone
+4571116050
Email
info@biogenity.com
Website
https://biogenity.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -71 | -115 | 97 | 1.251 | 2.397 | 1.899 | 1.388 |
| Staff expenses | -0 | -173 | -768 | -1.333 | -1.810 | -2.331 | -1.947 |
| EBITDA | -71 | -289 | -671 | -82 | 587 | -432 | -559 |
| Depreciation & amort. | -2 | -28 | -28 | -26 | -0 | -0 | -0 |
| EBIT | -74 | -317 | -699 | -108 | 587 | -432 | -559 |
| Net financials | 255 | 409 | 850 | -29 | -10 | -10 | -23 |
| Profit before tax | 181 | 92 | 151 | -137 | 577 | -442 | -582 |
| Tax | 40 | 21 | 34 | -30 | 128 | -99 | -129 |
| Net profit | 141 | 72 | 117 | -108 | 449 | -343 | -454 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 184 | 323 | 502 | 650 | 1.481 | 1.054 | 1.762 |
| Equity | 141 | 133 | 250 | 143 | 607 | 264 | -190 |
| Long-term debt | 0 | 80 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 39 | 108 | 252 | 508 | 874 | 790 | 1.951 |
| Total debt | 39 | 188 | 252 | 508 | 874 | 790 | 1.951 |
EBITDA margin
-40.3%
This company
15.8%
Market median
-355% vs market
20192025
Equity ratio
-10.8%
This company
38.2%
Market median
-128% vs market
20192025
Return on equity
-45375300.0%
This company
18.4%
Market median
-246604991% vs market
20192025
Net profit margin
-32.7%
This company
8.1%
Market median
-504% vs market
20192025
Asset turnover
0.79×
This company
1.12×
Market median
-29% vs market
20192025
Debt / equity
10.28×
This company
0.62×
Market median
-1558% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-30 – 2019-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KK Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Deputy Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Kastaniegaard Holding ApS | Company | 50.0% | 50.0% | 2018 |
L.Loeb Holding ApS | Company | 50.0% | 50.0% | 2018 |
SBJensen Holding IVS | Company | 33.3% | 33.3% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
L.Loeb Holding ApS
Biogenity ApS Board members of Biogenity ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kenneth Kastaniegaard | Chief Executive Officer | 0 companies |
| Louis Loeb | Chairman | 0 companies |
| Søren Buch Jensen | Deputy Chairman | 0 companies |